Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 98.50
Bid: 97.00
Ask: 100.00
Change: 0.50 (0.51%)
Spread: 3.00 (3.093%)
Open: 98.00
High: 98.50
Low: 98.00
Prev. Close: 98.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Futura Medical shares rise on US FDA agreement

Mon, 22nd Mar 2021 11:22

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Futura Medical, up 71% at 78.70 pence, 12-month range 7.65p-84p. The pharmaceutical company reaches an agreement with the US Food & Drug Administration for further studies into its erectile dysfunction treatment. The FDA agreed to a confirmatory clinical study for MED3000 to be conducted. The study will be known as FM71. The FM71 will be conducted before formal regulatory submission as a DeNovo Medical Device.

----------

88 Energy, up 28% at 1.44p, 12-month range 0.2p-1.8p. The Alaska-focused oil producer says Merlin-1 production hole drilling is to commence imminently at its project Peregrine in the NPR-A region of the North Slope of Alaska. 88 Energy reports that the Merlin-1 surface hole was successfully drilled to 1,512 feet as planned.

----------

EQTEC, up 19% at 2.26p, 12-month range 0.13p-3.17p. The gasification technology company says financial forecasts indicate profitability in 2021 as its pipeline continues to grow. For 2020, the company expects to report a loss no lower than EUR4 million, before any potential one-off adjustments. For 2021, EQTEC is targeting contracted sales growth from six to eight projects across Europe. Revenue is forecast to be approximately EUR15 million in 2021, with positive earnings before interest, taxes, depreciation and amortisation, which would make 2021 EQTEC's first year of profitability.

----------

Tremor International, up 15% at 700p, 12-month range 96.12p-716.30p. The video advertising technology firm upped its annual guidance as it kicked off 2021 with improved trading during its traditionally weaker quarter. Tremor expects net revenue between USD55 million and USD60 million in the first quarter, up as much as 87% from USD32.1 million a year earlier.

----------

Cambria Automobiles, up 12% at 74p, 12-month range 0p-89.74p. The franchised motor retailer gives consent to members of its management team exploring the potential acquisition of all shares in the company they do not own. Chief Executive Officer Mark Lavery, Finance Director James Mullins and Motor division Managing Director Tim Duckers are exploring the potential acquisition of shares in Cambria at 80 pence in cash per share. As Cambria has 100.0 million shares issued overall, it would mean that at most 60.0 million shares would be up for acquisition, valued at GBP39.6 million based on Friday's closing share price of 66.00p.

----------

Faron Pharmaceuticals, up 12% at 350.25p, 12-month range 216.05p-595p. The Finland-based biopharmaceutical company notes data which showed "significant survival benefit" in patients responding to cancer treatment bexmarilimab. Company says this is "very exciting data" supporting bexmarilimab's unique mechanism of action and adding to the accumulating evidence of bexmarilimab's broad potential across a range of hard-to-treat cancers.

----------

AIM - LOSERS

----------

Mobile Streams, down 36% at 0.29p, 12-month range 0.08p-0.52p. The mobile content and data intelligence firm raises GBP2.0 million through an oversubscribed placing, which will go towards providing working capital as well as firepower for potential acquisition opportunities. Mobile Streams issued 800.0 million shares at a price of 0.25p each, through a placing arranged by broker Peterhouse Capital. The placing price reflects a 43% discount to Mobile Streams' closing price on Friday of 0.44p.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Jul 2019 10:20

Faron Pharma Pleased By MATINS Progress And Plans To Increase Capacity

(Alliance News) - Faron Pharmaceuticals Oy said on Friday its MATINS study of nine cancer patients is progressing well, and it is planning to expand the clinical trial to more countries.The

Read more
26 Jun 2019 11:52

Faron Pharmaceuticals Says Traumakine Study Hindered By Steroid Use

(Alliance News) - Faron Pharmaceuticals Oy on Wednesday said interim results from its phase two Inforaaa study support continuation but the study is limited by a lack of patients not also taking a

Read more
14 Jun 2019 11:54

Faron Pharmaceuticals' Analysis Explains "Disappointing" Prior Trial

(Alliance News) - Faron Pharmaceuticals Oy on Friday said analysis of a more recent trial of Traumakine has explained why the drug did not perform as expected in a previous trial.Shares in

Read more
14 Jun 2019 10:37

Faron Pharmaceuticals reports 'significant' findings from YODA study

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced results from its pharmacokinetic/dynamic 'YODA' study examining the administration of concomitant steroids and Traumakine in healthy volunteers on Friday.

Read more
24 May 2019 13:34

Faron Pharma Finance Head Wichmann Steps Down, Hanninen Replaces

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Friday said it has made several managerial changes, which it believes will strengthen its operating performance.The clinical stage said

Read more
24 May 2019 11:50

Faron appoints new CFO after some internal shuffling

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals updated the market on its board and management team on Friday, announcing that Yrjö Wichmann was leaving his current role as its chief financial officer to take up the new position of vice-president, financing and investor relations.

Read more
14 May 2019 14:16

Faron Pharmaceuticals Raises EUR1.3 Million Via Share Subscription (ALLISS)

LONDON (Alliance News) - Biopharmaceutical company Faron Pharmaceuticals Ltd said Tuesday that it has raised EUR1.3 million via share subscription.The company has issued 1.8 million shares

Read more
7 May 2019 11:44

Faron Pharmaceuticals Narrows Loss On Reduced Clinical Trial Costs

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Tuesday reported a slightly narrowed annual loss as the drug developer's research & development costs fell.Faron is a clinical

Read more
2 May 2019 17:30

Faron Pharmaceuticals Knows Of No Reason For 43% Share Price Jump

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.Faron noted Thursday's 43% share price rise, and said

Read more
30 Apr 2019 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 1 May J SainsburyFull Year ResultsConnect GroupHalf Year GroupQ1 Stock

Read more
29 Apr 2019 15:46

Faron Gets Results Of Traumakine Study From Japanese Licensing Partner

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said its Japanese licensing partner Maruishi Pharmaceutical Co Ltd has provided clinical trial results on its phase three Traumakine for

Read more
11 Apr 2019 12:13

Faron Pharmaceuticals To Focus On Colorectal Cancer In Clevegen Trial

LONDON (Alliance News) - Faron Pharmaceuticals Oy is to target colorectal cancer in its upcoming test programme for Clevegen, it said Thursday.The testing of Clevegen on patients with will

Read more
11 Apr 2019 11:22

Faron Pharmaceuticals upbeat on latest info from MATINS trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Thursday that the cohort expansion part of its phase 1 and 2 'MATINS' clinical trial, investigating the safety and efficacy of its wholly-owned novel precision cancer immunotherapy 'Clevegen', would begin with patients suffering from late-stage colorectal cancer as soon as the optimal dosing was determined.

Read more
26 Mar 2019 15:52

UPDATE: Faron Pharmaceuticals Raises EUR3.1 Million In Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday afternoon said it has raised EUR3.1 million pursuant to a placing announced earlier in the day.The company issued

Read more
26 Mar 2019 12:05

Faron Pharmaceuticals Optimistic For Traumakine As It Plans Fundraise (ALLISS)

LONDON (Alliance News) - Finland's Faron Pharmaceuticals Oy on Tuesday said it expects further disappointing results from Traumakine, as it plans a share placing.Faron is currently for

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.